Technology ID
TAB-2023
Biological/Research Material for HIV Vaccine Research
E-Numbers
E-258-2009-0
Lead Inventor
Moss, Bernard (NIAID)
Co-Inventors
Wyatt, Linda (NIAID)
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Status
Fully developed. Material has been used extensively in research.
Lead IC
NIAID
ICs
NIAID
Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines.
Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.
The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research.
Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.
The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research.
Commercial Applications
- Research reagents useful in research and development in the area of HIV/AIDS vaccines.
Licensing Contact: